« Return to News | Drug Sponsors

GSK expands Australian facility, creates 58 jobs

Friday, February 10, 2012 02:05 PM

GlaxoSmithKline (GSK) is investing roughly $64 million to expand its manufacturing and drug development activities in its Boronia facility near Melbourne, Australia.

The Boronia facility, which serves as GSK’s Australia headquarters, is the company’s largest sterile manufacturing facility, featuring eight filling machines, six packaging lines and state-of-the-art “blow-fill-seal” (BFS) technology. 

The project is expected to create 58 new “highly-skilled” jobs by 2017, double GSK’s BFS manufacturing capacity—which it would make available to local companies—and fund the creation of a pilot scale industrialization facility for new power and sterile liquid pharmaceuticals.

“This investment will build a sustainable manufacturing capability within the local community while driving manufacturing technology,” said site director Troy Webb.

The Boronia facility will continue to support GSK’s R&D collaboration with Monash Institute of Pharmaceutical Sciences to develop next-generation drugs.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.